BioCentury
ARTICLE | Clinical News

GSK2998728: Additional Phase II data

November 9, 2015 8:00 AM UTC

Additional data from 3 patients with TTR-related cardiomyopathy who completed 12 months of dosing in an investigator-initiated, open-label, U.S. Phase II trial showed that once-weekly 300 mg subcutaneous ISIS-TTRRx led to a mean reduction of 1.9% in left ventricular mass from baseline to 12 months vs. a mean increase of 14% in patients from a published natural history study. Patients in the trial had a mean baseline interventricular septum thickness of 2.03 cm vs. 1.9 cm for patients in the natural history study. ISIS-TTRRx also led to a 107 pg/mL mean reduction in B-type natriuretic peptide (BNP; NPPB) levels and a mean increase of 36 feet in 6-minute walk distance (6MWD). There have been no discontinuations, deaths or serious adverse events reported. Injection-site reactions have occurred in <2% of all injections and were predominately mild. Data were presented at the European Congress on Hereditary ATTR amyloidosis meeting in Paris. ...